Day One Biopharmaceuticals Q2 OJEMDA revenue rises

Overview

• Day One Q2 2025 OJEMDA rev up 310% yr/yr to $33.6 mln

• Company reports Q2 net loss of $30.3 mln

• Ended Q2 with $453.1 mln in cash, cash equivalents, and investments

Outlook

• Company expects full-year 2025 OJEMDA net product revenue of $140 mln to $150 mln

Result Drivers

• OJEMDA SALES - OJEMDA net product revenue increased 310% yr/yr to $33.6 mln, driven by higher prescription volumes

• PRESCRIPTION GROWTH - OJEMDA prescriptions exceeded 1,000 in Q2 2025, a 15% increase from Q1 2025

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Day One Biopharmaceuticals Inc is $25.00, about 73.1% above its August 4 closing price of $6.74

Press Release: ID:nGNX6y80Mx